| Bioactivity | BI 665915 is an orally active and potent 5-lipoxygenase-activating protein (FLAP) inhibitor. BI 665915 inhibits FLAP production that blocks LTB4 biosynthesis in mice. BI 665915 is promising for research of various inflammatory diseases, including respiratory and cardiovascular diseases[1]. |
| CAS | 1360550-04-4 |
| Formula | C24H26N8O2 |
| Molar Mass | 458.52 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Takahashi H, et al. Synthesis, SAR, and series evolution of novel oxadiazole-containing 5-lipoxygenase activating protein inhibitors: discovery of 2-[4-(3-{(R)-1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-1-cyclopropyl-ethyl}-[1, 2, 4] oxadiazol-5-yl)-pyrazol-1-yl]-N, N-dimethyl-acetamide (BI 665915)[J]. Journal of Medicinal Chemistry, 2015, 58(4): 1669-1690. |
BI 665915
CAS: 1360550-04-4 F: C24H26N8O2 W: 458.52
BI 665915 is an orally active and potent 5-lipoxygenase-activating protein (FLAP) inhibitor. BI 665915 inhibits FLAP pro
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.